Hikma Pharmaceuticals 관리

관리 기준 확인 2/4

Hikma Pharmaceuticals CEO는 Riad Mishlawi, Sep2023 에 임명되었습니다 의 임기는 1.17 년입니다. 총 연간 보상은 $ 1.55M, 21.5% 로 구성됩니다. 21.5% 급여 및 78.5% 보너스(회사 주식 및 옵션 포함). 는 £ 2.39M 가치에 해당하는 회사 주식의 0.06% 직접 소유합니다. 2.39M. 경영진과 이사회의 평균 재임 기간은 각각 1.2 년과 5.4 년입니다.

주요 정보

Riad Mishlawi

최고 경영자

US$1.6m

총 보상

CEO 급여 비율	21.5%
CEO 임기	1.2yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Riad Mishlawi 의 보수는 Hikma Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	US$285m
Mar 31 2024	n/a	n/a	US$238m
Dec 31 2023	US$2m	US$333k	US$190m

보상 대 시장: Riad 의 총 보상 ($USD 1.55M ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.25M ).

보상과 수익: Riad 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Riad Mishlawi (60 yo)

1.2yrs

테뉴어

US$1,552,833

보상

Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...

리더십 팀

이름	위치	테뉴어	보상	소유권
Said Samih Darwazah	Executive Chairman	17.3yrs	US$3.57m	0.38% £ 15.3m
Riad Mishlawi	CEO & Director	1.2yrs	US$1.55m	0.060% £ 2.4m
Mazen Samih Darwazah	Executive Vice Chairman & President of MENA	19.2yrs	US$2.84m	0.63% £ 25.0m
Khalid Waleed Al Nabilsi	Chief Financial Officer	13.8yrs	데이터 없음	0.20% £ 8.1m
Patricia Bousfield	Chief Information Officer	no data	데이터 없음	데이터 없음
Guy Featherstone	Associate Director of Investor Relations	no data	데이터 없음	데이터 없음
Samuel Park	General Counsel	no data	데이터 없음	데이터 없음
Bassam Wael Kanaan	Executive Vice President of Corporate Development and M&A	10.7yrs	데이터 없음	0.26% £ 10.3m
Hussein Arkhagha	Chief People Officer	1.2yrs	데이터 없음	데이터 없음
Susan Ringdal	Executive Vice President of Strategic Planning & Global Affairs	6.8yrs	데이터 없음	데이터 없음
William Larkins	President of Injectables Business	1.2yrs	데이터 없음	데이터 없음
Julie Hill	Senior Vice President of Corporate Quality Compliance/Health & Safety	less than a year	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: HIKL 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Said Samih Darwazah	Executive Chairman	17.3yrs	US$3.57m	0.38% £ 15.3m
Riad Mishlawi	CEO & Director	1.2yrs	US$1.55m	0.060% £ 2.4m
Mazen Samih Darwazah	Executive Vice Chairman & President of MENA	19.2yrs	US$2.84m	0.63% £ 25.0m
Victoria Hull	Senior Independent Non-Executive Director	2yrs	US$149.27k	데이터 없음
Mary Henderson	Independent Non-Executive Director	8.1yrs	US$176.38k	0.0032% £ 127.3k
John Castellani	Independent Non-Executive Director	8.7yrs	US$159.69k	0.0016% £ 62.9k
Mohammed Ali Khaldoun Al-Husry	Non-Executive Director	19.1yrs	US$116.72k	0.52% £ 20.9m
Douglas Hurt	Independent Non-Executive Director	4.5yrs	US$149.85k	0.0020% £ 80.8k
Deneen Vojta	Independent Non-Executive Director	2yrs	US$127.05k	0.00045% £ 17.9k
Cynthia Flowers	Independent Non-Executive Director	5.4yrs	US$134.68k	0.00050% £ 19.9k
Nabil Rizk	Chairman of West-ward Pharmaceuticals	no data	데이터 없음	데이터 없음
Laura Balan	Independent Non-Executive Director	2.1yrs	US$124.98k	데이터 없음

5.4yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: HIKL 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Hikma Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Hikma Pharmaceuticals PLC Announces Executive Changes

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Insider recently sold UK£543k worth of stock

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Recent updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 21% undervalued

Final dividend of US$0.47 announced

Full year 2023 earnings released: EPS: US$0.86 (vs US$0.84 in FY 2022)

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Announces US Launch of COMBOGESIC IV

Now 22% undervalued after recent price drop

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024

Hikma Pharmaceuticals PLC Provides Earnings Guidance for the Year 2023

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 250 Index

Now 21% undervalued

New minor risk - Insider selling

Insider recently sold UK£543k worth of stock

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

First half 2023 earnings released: EPS: US$0.59 (vs US$0.76 in 1H 2022)

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Hikma Exceeds 150 Injectable Medicines in the US with Launch of Dobutamine Injection, USP

Now 21% undervalued

Upcoming dividend of US$0.37 per share at 2.7% yield

Full year 2022 earnings released: EPS: US$0.84 (vs US$1.82 in FY 2021)

Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US

Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Hikma Pharmaceuticals PLC Announces Board Appointments

Investor sentiment improved over the past week

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 100 Index

Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., Launches RYALTRIS in US

Upcoming dividend of US$0.19 per share

First half 2022 earnings released

Hikma Pharmaceuticals plc Recommends Interim Dividend, Payable on 19 September 2022

Insufficient new directors

Insufficient new directors

Hikma Pharmaceuticals plc Announces Company Secretary Change

Hikma Pharmaceuticals PLC Announces Chief Executive Officer Changes

Hikma Pharmaceuticals PLC Approves Final Dividend for the Year 2021

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Custopharm Inc. from Water Street Healthcare Partners, LLC.

Upcoming dividend of US$0.36 per share

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hikma Pharmaceuticals PLC (LSE:HIK) announces an Equity Buyback for £300 million worth of its shares.

Hikma Pharmaceuticals PLC Provides Revenue Guidance for 2022

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Custopharm Inc. from Water Street Healthcare Partners, LLC for approximately $430 million.

Upcoming dividend of US$0.18 per share

First half 2021 earnings released: EPS US$1.07 (vs US$0.88 in 1H 2020)

Hikma Pharmaceuticals PLC Announces US FDA Approval of KLOXXADO

New 90-day low: UK£22.38

Full year 2020 earnings released: EPS US$1.83 (vs US$2.01 in FY 2019)

Revenue beats expectations

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 23, 2021

Eyevance Pharmaceuticals Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

Hikma Pharmaceuticals PLC to Report Fiscal Year 2020 Results on Feb 25, 2021

Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.

New 90-day low: UK£24.23

Hikma Pharmaceuticals PLC Provides Update on Generic Advair Diskus®

Hikma Pharmaceuticals PLC Launches Generic Advair Diskus®

New 90-day low: UK£24.51

Amarin Corporation plc Files Patent Infringement Lawsuit Against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate

Hikma Pharmaceuticals PLC Launches Icosapent Ethyl Capsules 1gm in the US

Hikma Pharmaceuticals plc Announces Board and Committee Changes

Hikma Pharmaceuticals PLC and Arecor Limited Expand Collaboration with New Agreement to Develop and Commercialize Ready-To-Administer Medicine

Hikma Pharmaceuticals PLC Updates on ANDA for Generic Advair Diskus

Hikma Pharmaceuticals PLC to Report November,2020 Results on Nov 05, 2020